chufangao/CTO huggingface dataset:
Clinical trial NCT03439839: Study of Safety, Efficacy, Tolerability, Pharmacokinetics and Pharmacodynamics of LNP023 in in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Official title: An Open Label, Single Arm, Multiple Dose Study to Assess Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of LNP023 When Administered in Addition to Standard of Care (SoC) in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) With Signs of Active Hemolysis
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 16.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-04-09
Primary completion date: 2020-04-22
Completion date: 2022-02-28
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Clinical trial NCT04901689: Leronlimab in Patients With Coronavirus Disease 2019 (COVID-19) With Need for Mechanical Ventilation or Extracorporeal Membrane Oxygenation
Official title: A Phase 3, Randomized, Double Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Leronlimab in Combination With Standard of Care for Patients With Coronavirus Disease 2019 (COVID-19) With Need for Mechanical Ventilation or Extracorporeal Membrane Oxygenation
Sponsor: Hospital Israelita Albert Einstein (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: SUSPENDED 
Why stopped: Pending DSMB evaluation
Enrollment: 316.0 (ESTIMATED)
Number of arms: 2.0
Start date: 2021-10-23
Primary completion date: 2023-02-28
Completion date: 2023-02-28
Plan to share individual participant data: NO
Clinical trial NCT04216797: Rectal Versus Oral Diazepam Administration in the Treatment of Levator Ani Syndrome
Official title: Rectal Versus Oral Diazepam Administration in the Treatment of Levator Ani Syndrome in Participants Who Have Not Responded to Physical Therapy Treatment: A Prospective Randomized Study
Sponsor: Swedish Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Enrollment was initially suspended due to COVID pandemic. As the number of cases subsided, enrollment was reopened but never regained momentum. PI has left the site.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-01-09
Primary completion date: 2023-02-21
Completion date: 2023-02-21
Plan to share individual participant data: NO
Clinical trial NCT05700864: NGF Treatment for Patients With Neuropathic Corneal Pain
Official title: Assessing the Efficacy of Recombinant Human Nerve Growth Factor (rhNGF) Treatment in Patients With Neuropathic Corneal Pain (NCP)
Sponsor: Tufts Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Funding of study was withdrawn
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-11-01
Primary completion date: 2023-12-01
Completion date: 2023-12-01
Plan to share individual participant data: NO
Clinical trial NCT04708314: An Open-Label Study of Golodirsen in Non-Ambulant Patients With Duchenne Muscular Dystrophy
Official title: An Open-Label Study to Evaluate the Safety of Golodirsen in Non-Ambulant Patients With Duchenne Muscular Dystrophy
Sponsor: Rare Disease Research, LLC (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: The Sponsor has decided to focus their resources on other areas of therapy.
Enrollment: 2.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-10-31
Primary completion date: 2021-05-13
Completion date: 2021-05-13
Clinical trial NCT05478031: A Phase 2a Study to Investigate REM0046127 in Mild to Moderate Alzheimer's Disease
Official title: A Randomized, Placebo-controlled, Double-blind, Parallel-group Phase 2a Exploratory Study With Placebo run-in to Investigate PK/PD Effects, Safety, Tolerability and Pharmacokinetics of REM0046127 Oral Suspension Compared With Placebo in Subjects With Mild to Moderate Alzheimer's Disease
Sponsor: reMYND (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Due to the event of repeated elevated transaminase levels in one subject - elevated ALT/AST up to 6x ULN in the absence of any other potential underlying cause - we have decided to terminate the study.
Enrollment: 14.0 (ACTUAL)
Number of arms: 3.0
Start date: 2022-06-07
Primary completion date: 2024-06-04
Completion date: 2024-06-04
Plan to share individual participant data: NO
Clinical trial NCT04499352: A Study to Test BI 754091 Alone or in Combination With BI 836880 in People Who Have Advanced Anal Cancer
Official title: An Open Label, Randomized Phase II Study of BI 754091 Alone or in Combination With BI 836880 in Patients With Chemotherapy Resistant, Unresectable, Metastatic Squamous Cell Carcinoma of the Anal Canal
Sponsor: Boehringer Ingelheim (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Not due to safety reasons (sponsor decision).
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-09-14
Primary completion date: 2020-10-19
Completion date: 2020-10-19
Plan to share individual participant data: NO
IPD sharing description: Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions: 1. studies in products where Boehringer Ingelheim is not the license holder; 2. studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; 3. studies conducted in a single center or targeting rare diseases (because of limitations with anonymization). For more details refer to: https://www.mystudywindow.com/msw/datasharing
Clinical trial NCT01994824: Preemptive Therapy of GVHD
Official title: Preemptive Therapy of Graft-vs-Host Disease Using Rabbit Antithymocyte Globulin
Sponsor: University of Calgary (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The trend was observed toward higher mortality among the patients receiving the intervention Thymoglobulin on day 8 after hematopoietic cell transplantation.
Enrollment: 70.0 (ACTUAL)
Number of arms: 1.0
Start date: 2014-01-31
Primary completion date: 2017-06-30
Completion date: 2021-09-27
Clinical trial NCT03214666: GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies
Official title: GTB-3550 (CD16/IL-15/CD33)Tri-Specific Killer Engager (TriKE®) for the Treatment of High Risk Myelodysplastic Syndromes, Refractory/Relapsed Acute Myeloid Leukemia and Advanced Systemic Mastocytosis
Sponsor: GT Biopharma, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Development of GTB-3550 halted due to development of the second generation camelid nanobody TriKE drug product, GTB-3650.
Enrollment: 12.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-01-01
Primary completion date: 2021-08-02
Completion date: 2021-09-29
Limitations and caveats: This trial was terminated due to plans to clinically advance a modified second generation TriKE, requiring a new phase 1 study. Given this early termination, the maximal tolerated dose was not reached and the study did not proceed to phase 2. As only 12 participants were enrolled, the outcomes are presented in summary/descriptive format only.
Clinical trial NCT04239014: A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment.
Official title: A Phase 2 Randomized, Multi-Centre Study to Investigate the Efficacy and Tolerability of a Second Maintenance Treatment in Patients With Platinum Sensitive Relapsed Epithelial Ovarian Cancer, Who Have Previously Received PARP Inhibitor Maintenance Treatment
Acronym: DUETTE
Sponsor: AstraZeneca (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Sponsor made the decision to terminate the DUETTE study based on the interim analysis of the VIOLETTE study (NCT03330847) investigating the combination of ceralasertib and Olaparib, where study closure was recommended due to insufficient efficacy.
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-08-07
Primary completion date: 2021-01-25
Completion date: 2021-01-25
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.~Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please re-refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Clinical trial NCT05961007: Evaluation of IBI302 Injection in nAMD or DME
Official title: A Dose Escalation Study to Evaluate the Safety and Tolerability of IBI302 Intravitreal Injection in Subjects With Neovascular Age-related Macular Degeneration and Diabetic Macular Edema AND A Multi-center, Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With Diabetic Macular Edema
Sponsor: Innovent Biologics (Suzhou) Co. Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: SUSPENDED 
Why stopped: Company strategy adjustment
Enrollment: 234.0 (ESTIMATED)
Number of arms: 2.0
Start date: 2021-11-18
Primary completion date: 2023-10-31
Completion date: 2024-04-30
Plan to share individual participant data: NO
Clinical trial NCT04794569: Tinzaparin Lead-In to Prevent the Post-Thrombotic Syndrome
Official title: Tinzaparin Lead-In to Prevent the Post-Thrombotic Syndrome Phase IV Pilot Study
Acronym: TILE
Sponsor: Sunnybrook Health Sciences Centre (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: funding discontinued
Enrollment: 9.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-11-15
Primary completion date: 2024-01-19
Completion date: 2024-01-19
Plan to share individual participant data: NO
Clinical trial NCT03073733: Safety and Efficacy of Intravitreal Injection of Human Retinal Progenitor Cells in Adults With Retinitis Pigmentosa
Official title: A Prospective, Multicenter, Randomized, Study of the Safety and Efficacy of Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Adult Subjects With Retinitis Pigmentosa (RP)
Sponsor: jCyte, Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 84.0 (ACTUAL)
Number of arms: 3.0
Start date: 2017-03-01
Primary completion date: 2020-11-13
Completion date: 2020-11-13
Baseline population: One subject received 4M dose prior to major protocol amendment that excluded this dose group; this subject is not included in the presented analyses
Plan to share individual participant data: NO
Clinical trial NCT03179605: Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing With DFD-06
Official title: An Open Label, Multicenter Study to Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing With DFD-06 in Pediatric Subjects With Moderate to Severe Plaque Psoriasis
Sponsor: Primus Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Difficulty in enrollment
Enrollment: 22.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-05-02
Primary completion date: 2019-06-03
Completion date: 2020-06-03
Limitations and caveats: Early termination due to low enrollment with completion of 12 to 16.9 years old group only; the planned 6 to 11.9 years of age did not enroll.
Plan to share individual participant data: NO
Clinical trial NCT03181529: Effects of Psilocybin in Major Depressive Disorder
Official title: Effects of Psilocybin in Major Depressive Disorder
Sponsor: Johns Hopkins University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 27.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-08-10
Primary completion date: 2020-12-02
Completion date: 2020-12-02
Clinical trial NCT02422368: The Effect of a New Antioxidant Combination (ASTED) on Moderate to Severe Thyroid Eye Disease
Official title: The Effect of a New Antioxidant Combination (ASTED) on Moderate to Severe Thyroid Eye Disease, a Double Blind Placebo Controlled Randomized Clinical Trial
Sponsor: Iran University of Medical Sciences (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: WITHDRAWN 
Why stopped: Do not access to the drug
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-09-01
Primary completion date: 2024-06-30
Completion date: 2024-11-30
Clinical trial NCT02149901: Water and Sudafed in Autonomic Failure
Official title: Effect of Drinking Water on the Pressor Response to Pseudoephedrine in Patients With Autonomic Failure
Sponsor: Vanderbilt University Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: TERMINATED 
Why stopped: funding terminated
Enrollment: 35.0 (ESTIMATED)
Number of arms: 4.0
Start date: 2014-10-31
Primary completion date: 2020-12-31
Completion date: 2020-12-31
Clinical trial NCT04141904: Tofacitinib in Depression (TIDE)
Official title: The Effects of the Anti-inflammatory Drug, Tofacitinib on Emotional and Reward Processing in Patients With Treatment-resistant Depression and Elevated High-sensitivity C-reactive Protein
Acronym: TIDE
Sponsor: University of Oxford (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Covid-19 pandemic
Enrollment: 2.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-02-10
Primary completion date: 2022-05-23
Completion date: 2022-05-23
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04372940: Tranexamic Acid in Gender Mastectomy
Official title: The Role of Tranexamic Acid in Aesthetic and Reconstructive Surgery
Sponsor: University of Wisconsin, Madison (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: due to COVID
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-01-31
Primary completion date: 2024-01-31
Completion date: 2024-01-31
Plan to share individual participant data: NO
Clinical trial NCT05140824: A Study to Evaluate the Safety, Tolerability, and PK Profile of Single and Multiple Doses TJ202 in Patient With Systemic Lupus Erythematosus
Official title: A Multicenter, Randomized, Double-blind, Placebo-Controlled, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Single and Multiple Doses of TJ202 in Patients With Systemic Lupus Erythematosus
Sponsor: TJ Biopharma Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Company development strategy adjustment
Enrollment: 1.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-12-30
Primary completion date: 2022-12-14
Completion date: 2022-12-14
Clinical trial NCT02840799: Effect of KNO3 Compared to KCl on Oxygen UpTake in Heart Failure With Preserved Ejection Fraction (KNO3CK OUT HFPEF)
Official title: Effect of KNO3 Compared to KCl on Oxygen UpTake in Heart Failure With Preserved Ejection Fraction (KNO3CK OUT HFPEF)
Sponsor: University of Pennsylvania (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 84.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-08-31
Primary completion date: 2022-08-31
Completion date: 2022-08-31
Limitations and caveats: Due to dispensing errors, nine participants didn't crossover. Overall study power was maintained. MRI completion varied across sites, leading to the discontinuation of this study component. MRI endpoints have a smaller N; interpret results cautiously. Myocardial circumferential strain wasn't quantified. Instead, longitudinal LV function, crucial for LV relaxation and filling, was quantified.
Plan to share individual participant data: NO
Clinical trial NCT04990804: Opioid Free vs. Standard Perioperative Pain Regimen for Anterior Cervical Discectomy and Fusion (ACDF) Surgery
Official title: Opioid Free vs. Standard Perioperative Pain Regimen for Anterior Cervical Discectomy and Fusion (ACDF) Surgery
Sponsor: Vanderbilt University Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Limitations of the prospective study design revealed that a retrospective study design would be better suited.
Enrollment: 8.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-08-01
Primary completion date: 2022-02-01
Completion date: 2022-02-01
Plan to share individual participant data: NO
Clinical trial NCT04497038: Cabozantinib in Patients With Advanced Hepatocellular Carcinoma With Child Pugh Class B Cirrhosis After First-Line Therapy
Official title: Phase 1/2 Trial to Evaluate Cabozantinib in Patients With Advanced Hepatocellular Carcinoma With Child Pugh Class B Cirrhosis After First-Line Therapy
Sponsor: University of Michigan Rogel Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: loss of funding
Enrollment: 3.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-08-06
Primary completion date: 2023-05-02
Completion date: 2023-05-02
Plan to share individual participant data: NO
Clinical trial NCT04556383: A Study With GB004 in Adult Subjects With Active Ulcerative Colitis (UC)
Official title: A Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate GB004 in Adult Subjects With Mild-to-moderate Active Ulcerative Colitis
Sponsor: Gossamer Bio Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Study terminated due to lack of treatment benefit.
Enrollment: 236.0 (ACTUAL)
Number of arms: 4.0
Start date: 2020-10-19
Primary completion date: 2022-06-01
Completion date: 2022-06-01
Plan to share individual participant data: NO
Clinical trial NCT04093024: A Study to Find Out How Nintedanib is Taken up in the Body and How Well it is Tolerated in Children and Adolescents With Interstitial Lung Disease (ILD)
Official title: A Double Blind, Randomised, Placebo-controlled Trial to Evaluate the Dose-exposure and Safety of Nintedanib Per os on Top of Standard of Care for 24 Weeks, Followed by Open Label Treatment With Nintedanib of Variable Duration, in Children and Adolescents (6 to 17 Year-old) With Clinically Significant Fibrosing Interstitial Lung Disease
Acronym: InPedILD®
Sponsor: Boehringer Ingelheim (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 39.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-12-03
Primary completion date: 2022-05-24
Completion date: 2022-05-24
Baseline population: Treated set (TS): The TS consisted of participants who were randomised to a treatment group and received at least one dose of study medication.
Limitations and caveats: In the protocol it was planned to communicate the end of trial (EoT) once 30 participants had completed pharmacokinetic (PK) sampling at Week 26 or prematurely discontinued the trial and PK data was confirmed as adequate.~When the EoT was communicated, no participant had reached Week 100 yet, thus Week 100 time points were not assessable and the trial was completed as per protocol.
Plan to share individual participant data: NO
IPD sharing description: Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization).~For more details refer to: https://www.mystudywindow.com/msw/datatransparency
Clinical trial NCT03052400: Efficacy of Mifepristone in Males With Type 2 Diabetes Mellitus
Official title: Efficacy of Mifepristone in Males With Type 2 Diabetes Mellitus
Sponsor: Charles Drew University of Medicine and Science (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: End of Funding
Enrollment: 8.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-02-03
Primary completion date: 2021-03-31
Completion date: 2021-05-31
Limitations and caveats: Administrative barriers and pandemic closures limited enrollment, curtailed several secondary outcome measures, and caused early termination of the study.
Plan to share individual participant data: YES
IPD sharing description: Data sharing as per NIH funding requirements
IPD time frame: After publication
IPD access criteria: Contact investigator
Clinical trial NCT02177071: A proSpective Randomized Controlled Trial comParing infliximAb-antimetabolites Combination Therapy to Anti-metabolites monotheRapy and Infliximab monothErapy in Crohn's Disease Patients in Sustained Steroid-free Remission on Combination Therapy
Official title: A proSpective Randomized Controlled Trial comParing infliximAb-antimetabolites Combination Therapy to Anti-metabolites monotheRapy and Infliximab monothErapy in Crohn's Disease Patients in Sustained Steroid-free Remission on Combination Therapy
Acronym: SPARE
Sponsor: Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 211.0 (ACTUAL)
Number of arms: 3.0
Start date: 2015-10-09
Primary completion date: 2021-06-30
Completion date: 2021-10-31
Clinical trial NCT04543279: Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia
Official title: Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia
Sponsor: Washington University School of Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Low accrual
Enrollment: 3.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-05-03
Primary completion date: 2022-07-01
Completion date: 2022-07-30
Baseline population: None of the participants in Part A received treatment on Part B.
Plan to share individual participant data: NO